顺铂联合吉西他滨循环热灌注化疗对肝癌腹腔积液患者恶性肿瘤特异性生长因子、癌胚抗原水平的影响

目的探讨顺铂联合吉西他滨循环热灌注化疗对肝癌腹腔积液患者恶性肿瘤特异性生长因子(TSGF)和癌胚抗原(CEA)水平的影响。方法选取医院2016年1月至2019年1月收治的原发性肝癌腹腔积液患者80例,随机分为观察组和对照组,各40例。对照组患者采用常规治疗方案干预,观察组患者采用顺铂联合吉西他滨循环热灌注化疗。结果观察组治疗总有效率为92.50%,显著高于对照组的65.00%(P<0.05);治疗后,观察组患者卡氏生活质量评分(KPS)稳定率为37.50%,明显高于对照组的12.50%(P<0.05);治疗后,观察组患者的TSGF及CEA水平均明显低于对照组(P<0.05);两组均出现轻微不良反应,主要表现为恶心呕吐和骨髓抑制,且经对症治疗后均有效缓解,两组均未出现Ⅲ度或Ⅳ度不良反应。结论顺铂联合吉西他滨循环热灌注化疗方案可有效改善肝癌腹腔积液患者的病情,并降低血清TSGF和CEA水平。

Effect of Cisplatin Combined with Gemcitabine Circulating Hyperthermic Perfusion Chemotherapy on the Levels of Tumor-Specific Growth Factor and Carcinoembryonic Antigen in Patients with Hepatocellular Carcinoma with Peritoneal Effusion

Objective To investigate the effect of cisplatin combined with gemcitabine circulating hyperthermic perfusion chemotherapy on the levels of tumor-specific growth factor(TSGF)and carcinoembryonic antigen(CEA)in patients with hepatocellular carcinoma with peritoneal effusion.Methods Totally 80 patients with primary hepatocellular carcinoma with peritoneal effusion admitted to our hospital from January2016 to January 2019 were selected and randomly divided into the observation group and the control group,40 cases in each group.The patients in the control group were treated with routine treatment,while the patients in the observation group were treated with cisplatin combined with gemcitabine circulating hyperthermic perfusion chemotherapy.Results The total effective rate of the observation group was92.50%,which was significantly higher than 65.00%of the control group(P<0.05).After treatment,the stable rate of Karnofsky Performance Scale(KPS)score in the observation group was 37.50%,which was significantly higher than 12.50%in the control group(P<0.05).After treatment,the levels of TSGF and CEA in the observation group were significantly lower than those in the control group(P<0.05).Mild adverse reactions occurred in both groups,mainly nausea and vomiting and bone marrow suppression,which were effectively relieved after symptomatic treatment.There were no gradeⅢorⅣadverse reactions in both groups.Conclusion Cisplatin combined with gemcitabine cyclic hyperthermic perfusion chemotherapy can effectively improve the condition of patients with hepatocellular carcinoma with peritoneal effusion,and reduce the levels of TSGF and CEA.